The epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor of the Erb family, is overexpressed in both primary and metastatic RCC (4–6) suggesting the potential of anti-EGFR agents as therapeutics for the treatment of RCC. This evidence concerns the gene EGFR and renal cell carcinoma.